|

Heart Disease Clinical Trials in Sacramento, CA

38 recruiting studies within 50 miles

Phase
Trial Phase Dist.
S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac ToxicityPhase 3<1 mi
A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and ChemotherapyPhase 3<1 mi
A Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients With Heart Failure Who Are Intolerant or Not Eligible for Treatment With Steroidal Mineralocorticoid Receptor AntagonistsPhase 3<1 mi
Trial to Evaluate Safety And Effectiveness of Mechanical Circulatory Support in Patients With Advancing Heart FailureN/A<1 mi
Factors Affect Outcomes in Cardiovascular Surgery<1 mi
REdo tranScatheter Aortic Valve Replacement for Transcatheter aOrtic Valve failuRE<1 mi
Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection FractionPhase 3<1 mi
Digital Monitoring for Patients Post Coronary Interventions to Reduce Risk for Recurrent Adverse Cardiovascular EventsN/A<1 mi
Horizon 360 Protocol for the Treatment of Paroxysmal Atrial Fibrillation With the Sphere-360™ Catheter and Affera™ Mapping and Ablation System (Horizon 360)N/A<1 mi
The Rhythm Evaluation for AntiCoagulaTion With Continuous Monitoring of Atrial FibrillationPhase 3<1 mi
A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure PatientsPhase 3<1 mi
PARTNER 3 Trial - Aortic Valve-in-ValveN/A<1 mi
Heart Failure Precision Medicine StudyN/A<1 mi
Trial Investigating the Efficacy and Safety of Weekly Lonapegsomatropin Compared to Daily Somatropin in Children and Adolescents With Short Stature or Growth Failure Due to Growth Hormone Sufficient DisordersPhase 3<1 mi
Anticoagulation in ICH Survivors for Stroke Prevention and RecoveryPhase 3<1 mi
HeartShare: Combining Omics, Deep Phenotyping, and Electronic Health Records for Heart Failure Subtypes and Treatment Targets<1 mi
A Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients With Heart Failure (CONFIRMATION-HF)Phase 3<1 mi
Natural History Study in Pediatric Patients With MYBPC3 Mutation-associated Cardiomyopathy<1 mi
The Fourth Left Atrial Appendage Occlusion StudyN/A<1 mi
Pediatric Influence of Cooling Duration on Efficacy in Cardiac Arrest Patients (P-ICECAP)N/A<1 mi
Percutaneous Intervention Versus Observational Trial of Arterial Ductus in Low Weight InfantsN/A<1 mi
National Collaborative to Improve Care of Children With Complex Congenital Heart Disease<1 mi
Assessment of CCM in HF With Higher Ejection FractionN/A<1 mi
Cephea Early Feasibility StudyN/A<1 mi
Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With DapagliflozinPhase 3<1 mi
Pivotal Study of the SUpira System in Patients Undergoing High-Risk Percutaneous COronaRy InTervention (HRPCI)N/A<1 mi
ALLIANCE: Safety and Effectiveness of the SAPIEN X4 Transcatheter Heart ValveN/A<1 mi
Modeling Mortality in Duchenne Muscular Dystrophy Cardiomyopathy: Identification of Surrogate Outcome Measures for DMD Drug Trials<1 mi
Supporting Mental Health and Reducing Care Stress in Caregivers of Persons With Cardiovascular DiseaseN/A<1 mi
Examining Relationships Between Musculoskeletal Function Measurements of Movement Efficiency and Nervous System Function After Chronic Stroke<1 mi
Effects of Daily Beef Intake, as a Component of a Heart-Healthy Diet on Cellular ZincN/A14 mi
Dynamic Critical Congenital Heart Screening With Addition of Perfusion MeasurementsN/A14 mi
OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular EventsPhase 316 mi
Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)Phase 2/331 mi
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and ObesityPhase 345 mi
An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)Phase 345 mi
A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and ObesityPhase 345 mi
Product Surveillance Registry47 mi

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.